Free Trial

Helix BioPharma (TSE:HBP) Stock Price Passes Above Fifty Day Moving Average - Here's Why

Helix BioPharma logo with Medical background

Key Points

  • Helix BioPharma Corp. stock crossed above its 50-day moving average, reaching a high of C$1.08 during trading, while the average is C$0.96.
  • The company's market capitalization stands at C$57.26 million, with a negative PE ratio of -1.13 indicating a loss.
  • Helix BioPharma focuses on cancer drug development and is advancing therapies using proprietary technology in immuno-oncology.
  • Want stock alerts on Helix BioPharma? Get 5 Weeks of MarketBeat All Access for $5. Get My Stock Alerts.

Helix BioPharma Corp. (TSE:HBP - Get Free Report) crossed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of C$0.96 and traded as high as C$1.08. Helix BioPharma shares last traded at C$1.08, with a volume of 32,000 shares traded.

Helix BioPharma Price Performance

The company has a 50-day moving average of C$0.97 and a two-hundred day moving average of C$0.91. The stock has a market capitalization of C$57.26 million, a PE ratio of -1.13 and a beta of -0.84.

Helix BioPharma Company Profile

(Get Free Report)

Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidates are Tumor Defence Breaker L-DOS47, and, V-DOS47 among others.

Recommended Stories

Should You Invest $1,000 in Helix BioPharma Right Now?

Before you consider Helix BioPharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Helix BioPharma wasn't on the list.

While Helix BioPharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

$15 Billion for Cybersecurity: The Government’s Next Big Push
Tesla’s Future Unleashed: Elon’s Robotics Move Changes Everything
Top Trades: Massive Gains and Costly Mistakes to Avoid

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines